跳至主要内容
临床试验/JPRN-UMIN000041639
JPRN-UMIN000041639已完成未知

Prospective observational study to evaluate appropriate dose and efficacy of cephamycin and oxacephem for invasive UTI due to ESBL-E. coli - CMZ/FMOX for ESBL-E. coli UTI

CGM0 个研究点目标入组 78 人开始时间: 2020年9月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
CGM
入组人数
78

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients with a history of invasive urinary tract infection within 4 weeks prior to onset - Patients with concomitant use of antimicrobial agents (beta-lactams, aminoglycosides, fluoroquinolones, ST-fusions, colistin, tigecycline, minomycin, doxycycline, nitrofurantoin, and fosfomycin) that may be effective against ESBL-producing E. coli in addition to the study drug. - Persons with a history of hypersensitivity to cephem and carbapenem antibiotics - Dialysis patients (hemodialysis and peritoneal dialysis) - Other items that the principal investigator deems inappropriate for inclusion in the research

研究者

发起方
CGM

相似试验

Prospective observational study to evaluate... | 临床试验